SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.

This comes as part of Cordlife’s move to expand its diagnostics business, says the group in a press release issued on Wednesday.

Named Metascreen, the service uses urine instead of blood to detect over 100 inherited metabolic disorders – which is much more than what can be detected by conventional newborn metabolic screening tests currently available in Hong Kong, according to the group.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook